{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.2"},{"groupId":"OG001","value":"93.9"}]}],"title":"Any Grade TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.7"},{"groupId":"OG001","value":"54.5"}]}],"title":"Any Grade 3-4 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7"},{"groupId":"OG001","value":"48.1"}]}],"title":"Grade 3-4 TEAE excluding laboratory TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0"},{"groupId":"OG001","value":"53.9"}]}],"title":"Grade 3-4 TEAE excluding DP TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0"},{"groupId":"OG001","value":"47.4"}]}],"title":"Grade 3-4 TEAE excluding laboratory and DP TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.5"},{"groupId":"OG001","value":"43.2"}]}],"title":"Any Serious TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4"},{"groupId":"OG001","value":"19.5"}]}],"title":"Any TEAE leading to permanent discontinuation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"580"},{"groupId":"OG001","value":"595"}],"units":"Participants"}],"description":"Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. TEAEs: AEs that developed or worsened or became serious during on-treatment period. On-treatment period: The time from the first dose of treatment to 30 days after the last dose of treatment (either Cabazitaxel or Prednisone). A serious adverse event: Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. National Cancer Institute Common Terminology Criteria (NCI-CTCAE) version 4.03 (Grade 3 \\[severe\\] and Grade 4 \\[life-threatening\\]) was used in this study to grade clinical AEs.","groups":[{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"OG000","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"OG001","title":"Cabazitaxel 25 mg/m^2"}],"paramType":"NUMBER","populationDescription":"Safety population included all randomized participants who received at least one dose of the study drug during study treatment period.","reportingStatus":"POSTED","timeFrame":"From first administration of study treatment until 30 days after the last administration of study treatment (Maximum duration: 48 months)","title":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}